Friedreich Ataxia Clinical Trial
Official title:
Exploration of Transitional Life Events in Individuals With Friedreich's Ataxia: Implications for Genetic Counseling
The purposes of this study are to learn about significant life changes for people with
Friedreich's ataxia and about patients' experiences with health care providers. Friedreich's
ataxia is a rare genetic disorder in which patients experience progressive muscle weakness
and loss of coordination in the arms and legs. They may have other complications, such as
vision and hearing impairment, dysarthria, scoliosis, diabetes, and heart disease. The study
will explore the impact of this chronic progressive illness on transitional life events,
such as career choice and marriage, and the role of family members and health care
providers-particularly genetic counselors-in helping patients progress through these events.
Patients with Friedreich's ataxia who are 18 years of age or older may be eligible for this
study. Those enrolled will participate in a 45- to 60-minute interview by phone or in
person, in which they will be asked questions about important changes in their lives and
their past experiences with health care providers. The interview will be audiotaped.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Any individual diagnosed with Friedreich's ataxia, 18 years of age or older, who speaks English and is either in attendance at the NAF conference, or who has access to a telephone. EXCLUSION CRITERIA: Adolescents and children under the age of 18. Children and adolescents will be excluded due to the potiential for increased psychological and/or emotional. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Human Genome Research Institute (NHGRI) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Human Genome Research Institute (NHGRI) |
United States,
Beisecker AE, Cobb AK, Ziegler DK. Patients' perspectives of the role of care providers in amyotrophic lateral sclerosis. Arch Neurol. 1988 May;45(5):553-6. — View Citation
Bernhardt BA, Biesecker BB, Mastromarino CL. Goals, benefits, and outcomes of genetic counseling: client and genetic counselor assessment. Am J Med Genet. 2000 Sep 18;94(3):189-97. — View Citation
Borreani C, Gangeri L. Genetic counselling: communication and psychosocial aspects. Tumori. 1996 Mar-Apr;82(2):147-50. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05573698 -
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
|
Phase 1 | |
Completed |
NCT00229632 -
Idebenone to Treat Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT05579691 -
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT04273165 -
Safety and Efficacy of Etravirine in Friedreich Ataxia Patients
|
Phase 2 | |
Not yet recruiting |
NCT05874388 -
Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia
|
N/A | |
Completed |
NCT02594917 -
Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension
|
||
Completed |
NCT01716221 -
An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia
|
Phase 4 | |
Active, not recruiting |
NCT05485987 -
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
|
Phase 2 | |
Completed |
NCT03214588 -
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
|
Phase 2 | |
Completed |
NCT03418740 -
Neurology Measures in FA Children
|
||
Not yet recruiting |
NCT06054893 -
A Study of Omaveloxolone in Children With Friedreich's Ataxia
|
Phase 1 | |
Recruiting |
NCT04921930 -
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
|
Phase 1/Phase 2 | |
Completed |
NCT03933163 -
Micronised Resveratrol as a Treatment for Friedreich Ataxia
|
Phase 2 | |
Completed |
NCT02705547 -
Rosuvastatin (Crestor) in Friedreich Ataxia
|
Early Phase 1 | |
Completed |
NCT02035020 -
A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients
|
Phase 2 | |
Completed |
NCT00015808 -
Safety Study of Idebenone to Treat Friedreich's Ataxia
|
Phase 1 | |
Completed |
NCT04817111 -
NAD+ Precursor Supplementation in Friedreich's Ataxia
|
Phase 2 | |
Active, not recruiting |
NCT05168774 -
FRDA Investigator Initiated Study (IIS) With Elamipretide
|
Phase 1/Phase 2 | |
Completed |
NCT03917225 -
A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
|
Phase 2 | |
Completed |
NCT00224640 -
Iron-Chelating Therapy and Friedreich Ataxia
|
Phase 1/Phase 2 |